Novartis Ag (NVS) Operating Leases (2019 - 2026)

Novartis Ag has disclosed Operating Leases across 8 years of filings, most recently posting $1.7 billion for Q2 2026.

• In Q2 2026, Operating Leases rose 4.33% year-over-year to $1.7 billion; the TTM figure through Jun 2026 stood at $1.7 billion (up 4.33% YoY), while the FY2025 annual figure was $1.7 billion, up 5.68% from the prior year.
• Operating Leases came in at $1.7 billion for Q2 2026 at Novartis Ag, roughly flat from $1.7 billion in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $1.7 billion in Q1 2026 to a low of -$12.0 million in Q1 2022.
• Average Operating Leases over 5 years is $1.5 billion, with a median of $1.6 billion recorded in 2024.
• Year-over-year, Operating Leases tumbled 100.73% in 2022 and soared 13341.67% in 2023.
• Over 5 years, Operating Leases stood at $1.5 billion in 2022, then advanced by 3.9% to $1.6 billion in 2023, then slipped by 1.88% to $1.6 billion in 2024, then climbed by 5.68% to $1.7 billion in 2025, then grew by 0.36% to $1.7 billion in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $1.7 billion in Q2 2026, $1.7 billion in Q1 2026, and $1.7 billion in Q4 2025.